Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for MNTA
9.40
-0.08 (-0.84%)
After Hours: 9.40 0.00 (0.00%)
May 5, 4:42PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.97 - 9.70
52 week 7.86 - 25.56
Open 9.53
Vol / Avg. 577,745.00/508,563.00
Mkt cap 687.64M
P/E     -
Div/yield     -
EPS -1.31
Shares 70.92M
Beta 1.85
Inst. own 86%
Aug 2, 2016
Q2 2016 Momenta Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 8, 2016
Momenta Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 10:30AM EDT - Add to calendar
May 10, 2016
Momenta Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference - 1:00PM EDT - Add to calendar
May 4, 2016
Momenta Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 3, 2016
Q1 2016 Momenta Pharmaceuticals Inc Earnings Release
May 3, 2016
Q1 2016 Momenta Pharmaceuticals Inc Earnings Call
Mar 15, 2016
Momenta Pharmaceuticals Inc at Barclays Global Healthcare Conference - Webcast
Mar 7, 2016
Momenta Pharmaceuticals Inc at Cowen Health Care Conference
Feb 23, 2016
Momenta Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference
Feb 18, 2016
Q4 2015 Momenta Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -130.24% -92.93%
Operating margin -131.96% -94.18%
EBITD margin - -84.14%
Return on average assets -27.23% -24.60%
Return on average equity -30.65% -28.91%
Employees 258 -
CDP Score - -

Address

675 W Kendall St
CAMBRIDGE, MA 02142-1110
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Company’s product, a generic version of Lovenox (enoxaparin sodium injection), was approved by the United States Food and Drug Administration. The Company is developing Complex Generics, such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars, including M923 and M834. The Company is developing Novel Therapeutics, including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923, a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 64
Bio & Compensation  - Reuters
Michael Franken M.D. President - Biosimilars Business, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Matthew P Ottmer Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Ganesh Venkataraman Kaundinya Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Bruce A. Leicher Senior Vice President, General Counsel, Secretary
Age: 59
Bio & Compensation  - Reuters
John E. Bishop Ph.D. Senior Vice President - Pharmaceutical Sciences
Age: 53
Bio & Compensation  - Reuters
James M. Roach M.D. Senior Vice President - Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Director
Age: 54
Bio & Compensation  - Reuters